(BFM Stock Exchange) – French biotech may run out of cash by the end of April if it does not find additional funding to continue to develop. The action suffers on the Paris Stock Exchange.

DBV Technologies starts the week in hard. On the Paris Stock Exchange, the Biotechnology Company of 10.3% this Monday, March 24, around 3:00 p.m., in the wake of the publication of degraded accounts in 2024. Its title even dropped more than 25%, at 0.679 euros at the height of the session, in extensive volumes already representing more than six times the volumes exchanged on Friday.

DBV Technologies has once again been in deficit. The company says it has suffered a net loss of $ 113.9 million, against a net loss of $ 72.7 million on December 31, 2023.

A delicate financial situation

Its cash position is 32.55 million dollars at the end of December 2024 against 141.4 million dollars on December 31, 2023. The biotechnology company therefore consumed $ 108.9 million cash over one year, due to external clinical expenses and regulatory and industrial activities related to the 3 phase 3 clinical trial on its Patch Viaskin Peanut and The fourth quarter of 2025.

The company recalls suffering from operating losses and negative cash flows since its creation, namely since 2002.

DBV Technology explains that its available cash flow will only allow it to finance its operations until April 2025. Back to the wall, DBV Technologies says (logically) to be looking for additional funds.

“If the company cannot achieve its financing objectives, it could be required to reduce its activities, in particular by delaying or reducing its research and development efforts, to obtain funding through agreements with potential counterparts, which could force it to give up its rights on candidate products that it could develop or market independently, or to stop all or part of its activities”, advance DBV Technologies.

At the crossroads

DBV Technologies is at the crossroads. If on the financial level, the situation is therefore critical, the company is advancing well on the regulatory aspect.

In parallel with its financial results, DBV Technologies also mentioned an agreement with the Food and Drug Administration (FDA) The American health authority, which accepted that the innocent data of the phase 3 speed study (for “Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Effectcy”) for the Patch Viaskin Peanut Children aged 4 to 7 are sufficient to support a BLA deposit (that is to say the demand for a biological license, editor’s note) on this age group.

Thus, the Comfort complementary study on the security of the Patch Viaskin Peanut, a patch against peanut allergy, in children aged 4 to 7 is no longer necessary.

The deposit of the blah for the viaskin peanut patch in children aged 4 to 7 is now planned for the first half of 2026. The company anticipates that this could accelerate the marketing of the product by approximately one year, if it is approved by the FDA.

A little earlier in the year, DBV Technologies had revealed positive results of a study of its clinical phase III clinical trial (the last step before a potential marketing of a product) “Epitope”. These results made it possible to obtain efficiency data over 36 months, against 12 months initially to process food allergy to peanuts in very young children.

This had allowed DBV Technologies to revive the stock market winning almost 80% over the first week of 2025, and to display more 24% gains since the start of the year. But by diszoaming, the balance sheet is less flattering. The company has indeed erased almost all of its value since its October 2017 record at more than 85 euros …